亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

安徽聯(lián)創(chuàng)藥物化學有限公司  

醫(yī)藥中間體,醫(yī)藥原料藥

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人:葛經(jīng)理
  • 電話:0551-68596228
  • 郵件:sales@lcywhx.com
  • 傳真:0551-68596338
  • QQ:2649585961
站內(nèi)搜索
 
榮譽資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產(chǎn)品 > 托格列凈,1201913-82-7
托格列凈,1201913-82-7
單價 面議對比
詢價 暫無
發(fā)貨 安徽合肥市付款后3天內(nèi)
品牌 安徽聯(lián)創(chuàng)
分子式 C22H26O6.H2O
分子量 404.45
CAS 登錄號 1201913-82-7
過期 長期有效
更新 2015-03-02 15:08
 
詳細信息
 基本信息 
英文名  Tofogliflozin hydrate (1:1) 
別名  (1S,3'R,4'S,5'S,6'R)-6-[(4-Ethylphenyl)methyl]-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro[isobenzofuran-1(3H),2'-[2H]pyran]-3',4',5'-triol hydrate (1:1) 
產(chǎn)品名稱  托格列凈一水合物(1:1) 
分子式 C22H26O6.H2O 
分子量 404.45 
CAS 登錄號 1201913-82-7
©2025 安徽聯(lián)創(chuàng)藥物化學有限公司 版權所有   技術支持:化工網(wǎng)   訪問量:20863  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |